4T07 Syngeneic Model Overview

The 4T07 syngeneic model is a well-characterized murine model of mammary carcinoma derived from the same spontaneous BALB/c mouse tumor as the 4T1 line. While genetically related to 4T1, the 4T07 cell line exhibits a moderately aggressive phenotype with limited metastatic dissemination, making it particularly useful for studying early immune interactions and tumor progression in an immunocompetent host. Tumors established with 4T07 cells grow rapidly at the primary site but generate few macroscopic metastases, reflecting a locally invasive yet non-lethal disease course that closely parallels early-stage triple-negative breast cancer (TNBC) in humans.

The 4T07 model retains an intact immune microenvironment, allowing for comprehensive analysis of tumor-immune cross talk, immune editing, and the mechanisms underlying immune-mediated tumor control. It is widely employed in studies evaluating immunotherapy response kinetics, immune memory formation, and the balance between effector and regulatory cell populations during tumor progression. This model’s intermediate aggressiveness between the non-metastatic 67NR and highly metastatic 4T1 lines makes it a critical comparative system for evaluating how immunotherapeutic interventions alter tumor evolution in vivo.

Request a Custom Quote for 4T07 Syngeneic Model

Biological and Molecular Characteristics

The 4T07 cell line originates from the same spontaneous mammary tumor as the 4T1 family of BALB/c-derived breast cancer models but demonstrates a reduced capacity for systemic metastasis. Like 4T1, 4T07 cells exhibit epithelial morphology and express a triple-negative receptor profile, lacking ER, PR, and HER2 expression. Tumors generated from 4T07 cells are moderately proliferative, display a cohesive growth pattern, and exhibit infiltration by a diverse range of immune cells including macrophages, neutrophils, and T lymphocytes. The cytokine environment in 4T07 tumors is characterized by elevated CXCL1, CCL2, and GM-CSF expression, which recruit myeloid-derived suppressor cells (MDSCs) and promote local immune suppression.

Parameter	Description
Host strain	BALB/c (female, 6–8 weeks)
Tumor origin	Spontaneous mammary carcinoma (mouse)
Receptor status	ER– / PR– / HER2–
Inoculation route	Orthotopic (mammary fat pad) or subcutaneous
Tumor take rate	>90%
Doubling time	Approximately 3–4 days in vivo
Metastatic potential	Low to moderate; micrometastases detectable in lungs
Immunophenotype	Mixed infiltration of myeloid and lymphoid cells
Common applications	Immunotherapy, tumor dormancy, immune surveillance studies

In Vivo Model Development and Tumorigenicity

Orthotopic implantation of 4T07 cells into the mammary fat pad of BALB/c mice results in reproducible tumor formation with a high take rate and consistent growth kinetics. Palpable nodules typically emerge within seven to ten days following inoculation. Primary tumors expand steadily but infrequently progress to extensive systemic metastasis, providing an advantageous model for evaluating therapeutic agents that modulate the primary tumor immune microenvironment without the confounding effects of widespread dissemination.

The model’s intermediate growth rate compared to 4T1 allows for detailed longitudinal analysis of immune infiltration, cytokine signaling, and therapeutic effects over extended observation periods. Subcutaneous implantation produces similarly consistent tumor growth and is often employed in early-stage immunotherapy screening studies. The 4T07 model’s well-defined tumor kinetics and predictable immune engagement make it ideal for mechanistic investigations into tumor immune evasion, dormancy, and immunoediting.

Request a Custom Quote for 4T07 Syngeneic Model

Histopathology and Immunohistochemical Profile

Histopathological analysis reveals that 4T07 tumors form solid epithelial masses with moderate vascularization and focal necrosis. The architecture is characterized by densely packed tumor cells surrounded by fibrotic stroma and infiltrated by host immune cells, particularly macrophages and T lymphocytes. Compared to 4T1 tumors, 4T07 lesions display less desmoplasia and reduced inflammatory cell density, correlating with their lower metastatic potential.

Immunohistochemical assessment shows strong nuclear Ki-67 staining consistent with an actively proliferating phenotype. Moderate PD-L1 expression is typically observed on both tumor and stromal cells, while F4/80 and CD11b markers indicate substantial macrophage and myeloid cell infiltration. CD3 and CD8 staining reveal moderate T-cell presence, suggesting partial immune activation within the tumor microenvironment. The relative equilibrium between proliferative activity and immune infiltration makes 4T07 an effective model for testing therapies aimed at shifting the tumor from an immunologically quiescent to an inflamed state.

Preclinical Applications and Drug Response

The 4T07 syngeneic model is widely used for preclinical research investigating immune checkpoint modulation, cytokine therapy, and adaptive immune memory formation. Its intermediate metastatic behavior allows researchers to study local tumor control and early immunological mechanisms that precede systemic spread. Checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 have demonstrated measurable effects on T-cell activation and tumor regression within this system, while adoptive T-cell transfer and dendritic cell vaccination approaches have been used to investigate immune priming and recall responses.

Because 4T07 tumors can enter a state of equilibrium following partial regression, this model provides unique insight into tumor dormancy and relapse, phenomena that are difficult to replicate in more aggressive systems. It is also used for evaluating novel adjuvants, RNA-based immune modulators, and combinational immunotherapies that rely on intact antigen presentation and immune surveillance. The 4T07 model thus serves as a valuable bridge between non-metastatic and metastatic breast cancer models, offering a balanced platform for dissecting immune-tumor interactions and the durability of therapeutic responses.

Request This Model

To request the 4T07 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for 4T07 Syngeneic Model